Arvind joined atai Life Sciences in 2021 as Vice President, Digital Strategy and Operations, and is responsible for establishing and implementing atai’s Digital Therapeutics and Precision Psychiatry strategy. Prior to joining atai, Arvind was the Chief Operating Officer of Oxford VR, where he was responsible for Operations, Strategy, and Business Development. Oxford VR received Breakthrough Device designation from the FDA for the treatment of serious mental illnesses and was acquired by US operator BehaVR in 2022.
Before joining Oxford VR, Arvind was an Investment Manager at Epiris Private Equity (“Epiris”), where he was responsible for the buy-out, management, and digital transformation of companies between £100m – £500m in valuation. At Epiris, Arvind deployed and exited over £400m and £200m of capital respectively and sat on 9 Executive Boards. Arvind started his professional career at NM Rothschild & Sons where he was Vice President, Healthcare Mergers & Acquisitions.
Arvind holds a Bachelor’s and Master’s degree in Molecular and Cellular Biochemistry from the University of Oxford with dissertations in Cell Cycle Replication (Professor Kearsey) and Vaccinology (Dame Professor Gilbert).